Identification

Name
Phenylbutazone
Accession Number
DB00812  (APRD00409, DB08343)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)

Structure
Thumb
Synonyms
  • 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine
  • 4-BUTYL-1,2-diphenyl-pyrazolidine-3,5-dione
  • 4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione
  • Fenilbutazona
  • Phenbutazone
  • Phenylbutazon
  • Phenylbutazone
  • Phenylbutazonum
External IDs
G-13871 / NSC-25134 / USAF Ge-15
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-butazone Tab 100mgTablet100 mgOralNovopharm Limited1976-12-312005-08-10Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Phenylbutazone Tab 100mgTablet100 mgOralApotex Corporation1976-12-312009-09-18Canada
International/Other Brands
Azolid
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Alka Phenyl TabPhenylbutazone (100 mg) + Aluminum hydroxide (100 mg) + Magnesium Trisilicate (150 mg)TabletOralDuchesnay Inc.1978-12-311997-08-11Canada
Alka Phenylbutazone TabPhenylbutazone (100 mg) + Aluminum hydroxide (100 mg) + Magnesium Trisilicate (150 mg)TabletOralPro Doc Limitee1974-12-311997-08-14Canada
Phenylone Plus TabPhenylbutazone (100 mg) + Aluminum hydroxide (100 mg) + Magnesium Trisilicate (150 mg)TabletOralMedic Laboratory LtÉe1978-12-311996-09-09Canada
Categories
UNII
GN5P7K3T8S
CAS number
50-33-9
Weight
Average: 308.3743
Monoisotopic: 308.152477894
Chemical Formula
C19H20N2O2
InChI Key
VYMDGNCVAMGZFE-UHFFFAOYSA-N
InChI
InChI=1S/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3
IUPAC Name
4-butyl-1,2-diphenylpyrazolidine-3,5-dione
SMILES
CCCCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of backache and ankylosing spondylitis

Structured Indications
Not Available
Pharmacodynamics

Phenylbutazone is a synthetic, pyrazolone derivative. It is a nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties and arise from its ability to reduce production of prostaglandin H and prostacyclin. Prostaglandins act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostacylcin causes vascular constriction platelet disaggregation

Mechanism of action

Phenylbutazone binds to and inactivates prostaglandin H synthase and prostacyclin synthase through peroxide (H2O2) mediated deactivation. The reduced production of prostaglandin leads to reduced inflammation of the surrounding tissues.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstacyclin synthase
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral, LD50 = 238 mg/kg (mouse); Oral, LD50 = 781 mg/kg (rabbit); Oral, LD50 = 245 mg/kg (rat); Oral, LD50 = 375 mg/kg (rat)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Phenylbutazone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with 5-androstenedione.Experimental, Illicit
AbciximabPhenylbutazone may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Phenylbutazone can be decreased when combined with Abiraterone.Approved
AcebutololPhenylbutazone may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Acemetacin.Approved
AcenocoumarolPhenylbutazone may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinPhenylbutazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Phenylbutazone.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid.Approved
AliskirenPhenylbutazone may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alminoprofen.Experimental
AlprenololPhenylbutazone may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Phenylbutazone.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Amcinonide.Approved
AmikacinPhenylbutazone may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmiloridePhenylbutazone may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Phenylbutazone can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinPhenylbutazone may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodPhenylbutazone may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Anisodamine.Investigational
annamycinPhenylbutazone may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Antipyrine.Approved
Antithrombin III humanPhenylbutazone may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanPhenylbutazone may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Apocynin.Investigational
ApramycinPhenylbutazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Phenylbutazone can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinPhenylbutazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinPhenylbutazone may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanPhenylbutazone may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Phenylbutazone.Approved, Investigational
ArotinololPhenylbutazone may decrease the antihypertensive activities of Arotinolol.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Atamestane.Investigational
AtenololPhenylbutazone may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phenylbutazone.Approved
BalsalazidePhenylbutazone may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminPhenylbutazone may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPhenylbutazone may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinPhenylbutazone may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Phenylbutazone.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Phenylbutazone.Approved
BenorilateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Phenylbutazone.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Betamethasone.Approved, Vet Approved
BetaxololPhenylbutazone may decrease the antihypertensive activities of Betaxolol.Approved
BevantololPhenylbutazone may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Phenylbutazone.Approved, Investigational
BisoprololPhenylbutazone may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPhenylbutazone may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPhenylbutazone may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bucillamine.Investigational
BucindololPhenylbutazone may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bufexamac.Experimental
BufuralolPhenylbutazone may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bumadizone.Experimental
BumetanidePhenylbutazone may decrease the diuretic activities of Bumetanide.Approved
BupranololPhenylbutazone may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Phenylbutazone.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Phenylbutazone.Experimental
CapecitabineThe metabolism of Phenylbutazone can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Phenylbutazone.Approved
CarbamazepineThe metabolism of Phenylbutazone can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Carbaspirin calcium.Experimental
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Phenylbutazone.Approved
CarprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololPhenylbutazone may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPhenylbutazone may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Castanospermine.Experimental
CeliprololPhenylbutazone may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Phenylbutazone can be increased when it is combined with Ceritinib.Approved
CertoparinPhenylbutazone may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Phenylbutazone.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Phenylbutazone.Approved
CholecalciferolThe metabolism of Phenylbutazone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Phenylbutazone.Approved
CinoxacinPhenylbutazone may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
Citric AcidPhenylbutazone may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Phenylbutazone.Vet Approved
CloranololPhenylbutazone may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Phenylbutazone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Phenylbutazone can be decreased when combined with Crisaborole.Approved
CurcuminThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Phenylbutazone.Experimental
CyclosporinePhenylbutazone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with D-Limonene.Investigational
Dabigatran etexilatePhenylbutazone may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Phenylbutazone can be decreased when it is combined with Dabrafenib.Approved
DalteparinPhenylbutazone may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPhenylbutazone may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPhenylbutazone may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinPhenylbutazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Phenylbutazone.Experimental
DelavirdineThe metabolism of Phenylbutazone can be decreased when combined with Delavirdine.Approved
DesirudinPhenylbutazone may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Phenylbutazone.Approved
DextranPhenylbutazone may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Phenylbutazone may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Phenylbutazone may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Phenylbutazone may increase the anticoagulant activities of Dextran 75.Approved
DibekacinPhenylbutazone may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Phenylbutazone.Approved, Vet Approved
DicoumarolPhenylbutazone may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Phenylbutazone.Approved
DihydrostreptomycinPhenylbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Phenylbutazone.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Phenylbutazone.Approved
DosulepinThe metabolism of Phenylbutazone can be decreased when combined with Dosulepin.Approved
DoxorubicinPhenylbutazone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenonePhenylbutazone may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Phenylbutazone is combined with E-6201.Investigational
Edetic AcidPhenylbutazone may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPhenylbutazone may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Phenylbutazone can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Phenylbutazone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Phenylbutazone.Approved
EnoxacinPhenylbutazone may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinPhenylbutazone may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Phenylbutazone.Experimental
EpanololPhenylbutazone may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Epirizole.Approved
EpirubicinPhenylbutazone may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenonePhenylbutazone may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Phenylbutazone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Phenylbutazone.Approved
EquileninThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Equilin.Approved
EsmololPhenylbutazone may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Estrone sulfate.Approved
Etacrynic acidPhenylbutazone may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Phenylbutazone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ethenzamide.Experimental
Ethyl biscoumacetatePhenylbutazone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etofenamate.Approved
EtravirineThe metabolism of Phenylbutazone can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Phenylbutazone.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Phenylbutazone.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Feprazone.Experimental
Ferulic acidPhenylbutazone may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Phenylbutazone.Approved
FleroxacinPhenylbutazone may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Phenylbutazone.Approved, Withdrawn
FloxuridineThe metabolism of Phenylbutazone can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with fluasterone.Investigational
FluconazoleThe metabolism of Phenylbutazone can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fludrocortisone.Approved
FluindionePhenylbutazone may increase the anticoagulant activities of Fluindione.Investigational
FlumequinePhenylbutazone may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Phenylbutazone can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Phenylbutazone.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Phenylbutazone.Approved, Investigational
FluvastatinThe metabolism of Phenylbutazone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Phenylbutazone can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Phenylbutazone.Approved, Nutraceutical, Vet Approved
FondaparinuxPhenylbutazone may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPhenylbutazone may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Phenylbutazone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Phenylbutazone.Approved
FosphenytoinThe metabolism of Phenylbutazone can be increased when combined with Fosphenytoin.Approved
FramycetinPhenylbutazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemidePhenylbutazone may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexatePhenylbutazone may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPhenylbutazone may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPhenylbutazone may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Phenylbutazone.Approved, Withdrawn
GemfibrozilThe metabolism of Phenylbutazone can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPhenylbutazone may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPhenylbutazone may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPhenylbutazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APhenylbutazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Phenylbutazone may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinPhenylbutazone may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Phenylbutazone is combined with HE3286.Investigational
HeparinPhenylbutazone may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Higenamine.Investigational
HydralazinePhenylbutazone may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Phenylbutazone.Approved
Hygromycin BPhenylbutazone may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Icatibant.Approved
IdarubicinPhenylbutazone may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxPhenylbutazone may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Phenylbutazone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Phenylbutazone.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Phenylbutazone.Approved
IndenololPhenylbutazone may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Phenylbutazone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Phenylbutazone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Indoprofen.Withdrawn
INNO-206Phenylbutazone may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Phenylbutazone can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinPhenylbutazone may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Istaroxime.Investigational
KanamycinPhenylbutazone may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Phenylbutazone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Phenylbutazone.Approved
LabetalolPhenylbutazone may decrease the antihypertensive activities of Labetalol.Approved
LandiololPhenylbutazone may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Phenylbutazone.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Phenylbutazone.Investigational
LeflunomideThe metabolism of Phenylbutazone can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinPhenylbutazone may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPhenylbutazone may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololPhenylbutazone may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPhenylbutazone may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Phenylbutazone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Phenylbutazone.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Phenylbutazone.Approved
LobeglitazoneThe metabolism of Phenylbutazone can be decreased when combined with Lobeglitazone.Approved
LonazolacThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lornoxicam.Approved
LosartanThe metabolism of Phenylbutazone can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Phenylbutazone can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Phenylbutazone.Approved, Investigational
LumacaftorThe serum concentration of Phenylbutazone can be decreased when it is combined with Lumacaftor.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Phenylbutazone.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Phenylbutazone can be decreased when combined with Manidipine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Phenylbutazone.Approved
ME-609The risk or severity of adverse effects can be increased when Phenylbutazone is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Phenylbutazone.Approved
MelagatranPhenylbutazone may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meloxicam.Approved, Vet Approved
MepindololPhenylbutazone may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazinePhenylbutazone may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Phenylbutazone.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenylbutazone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPhenylbutazone may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Phenylbutazone.Approved
MetoprololPhenylbutazone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamidePhenylbutazone may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinPhenylbutazone may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Phenylbutazone can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Phenylbutazone can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Phenylbutazone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Phenylbutazone.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Phenylbutazone.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Phenylbutazone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mycophenolic acid.Approved
NadololPhenylbutazone may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPhenylbutazone may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPhenylbutazone may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Phenylbutazone.Approved
Nalidixic AcidPhenylbutazone may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Phenylbutazone.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Phenylbutazone is combined with NCX 1022.Investigational
NeaminePhenylbutazone may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinPhenylbutazone may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPhenylbutazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nepafenac.Approved
NetilmicinPhenylbutazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Phenylbutazone can be decreased when combined with Nicardipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nitroaspirin.Investigational
NorfloxacinPhenylbutazone may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Phenylbutazone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Phenylbutazone.Approved
OlsalazinePhenylbutazone may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Phenylbutazone.Investigational
OmeprazoleThe metabolism of Phenylbutazone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Orgotein.Vet Approved
OtamixabanPhenylbutazone may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxaprozin.Approved
Oxolinic acidPhenylbutazone may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololPhenylbutazone may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Paramethasone.Approved
ParomomycinPhenylbutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Parthenolide.Investigational
PazufloxacinPhenylbutazone may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPhenylbutazone may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPhenylbutazone may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfatePhenylbutazone may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Phenylbutazone.Approved
PhenindionePhenylbutazone may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Phenylbutazone can be increased when combined with Phenobarbital.Approved
PhenprocoumonPhenylbutazone may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe metabolism of Phenylbutazone can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Phenylbutazone.Approved, Investigational
PindololPhenylbutazone may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidPhenylbutazone may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinPhenylbutazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanidePhenylbutazone may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pirfenidone.Investigational
Piromidic acidPhenylbutazone may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Phenylbutazone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pirprofen.Experimental
PlazomicinPhenylbutazone may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinPhenylbutazone may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Phenylbutazone.Approved
PractololPhenylbutazone may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Phenylbutazone.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Phenylbutazone can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Phenylbutazone can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Propacetamol.Approved
PropranololPhenylbutazone may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Phenylbutazone.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Phenylbutazone.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Phenylbutazone.Vet Approved
Protein CPhenylbutazone may increase the anticoagulant activities of Protein C.Approved
Protein S humanPhenylbutazone may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePhenylbutazone may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPhenylbutazone may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Phenylbutazone is combined with PTC299.Investigational
PuromycinPhenylbutazone may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Phenylbutazone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Phenylbutazone.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Phenylbutazone.Approved
QuinineThe metabolism of Phenylbutazone can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Phenylbutazone.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Phenylbutazone.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Resveratrol.Experimental, Investigational
ReviparinPhenylbutazone may increase the anticoagulant activities of Reviparin.Approved
RibostamycinPhenylbutazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Phenylbutazone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Phenylbutazone can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Risedronate.Approved, Investigational
RivaroxabanPhenylbutazone may increase the anticoagulant activities of Rivaroxaban.Approved
RosoxacinPhenylbutazone may increase the neuroexcitatory activities of Rosoxacin.Approved
RufloxacinPhenylbutazone may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinPhenylbutazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Phenylbutazone.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Phenylbutazone.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Phenylbutazone.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Phenylbutazone.Approved
SecobarbitalThe metabolism of Phenylbutazone can be increased when combined with Secobarbital.Approved, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Phenylbutazone can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinPhenylbutazone may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinPhenylbutazone may increase the neuroexcitatory activities of Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Phenylbutazone.Approved
SorafenibThe metabolism of Phenylbutazone can be decreased when combined with Sorafenib.Approved, Investigational
SotalolPhenylbutazone may decrease the antihypertensive activities of Sotalol.Approved
SP1049CPhenylbutazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinPhenylbutazone may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinPhenylbutazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Phenylbutazone.Approved
SpironolactonePhenylbutazone may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Phenylbutazone is combined with SRT501.Investigational
StreptomycinPhenylbutazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinPhenylbutazone may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Phenylbutazone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Phenylbutazone can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Phenylbutazone.Approved
SulfisoxazoleThe metabolism of Phenylbutazone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Phenylbutazone.Approved
SulodexidePhenylbutazone may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Phenylbutazone.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Suxibuzone.Experimental
TacrolimusPhenylbutazone may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Phenylbutazone.Approved
TalinololPhenylbutazone may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Phenylbutazone.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Phenylbutazone.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Phenylbutazone.Approved, Investigational
TemafloxacinPhenylbutazone may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Phenylbutazone.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Phenylbutazone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Teriflunomide.Approved
TertatololPhenylbutazone may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Phenylbutazone can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Phenylbutazone can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tiludronic acid.Approved, Vet Approved
TimololPhenylbutazone may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tixocortol.Approved
TobramycinPhenylbutazone may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Phenylbutazone can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Phenylbutazone.Approved
TopiroxostatThe metabolism of Phenylbutazone can be decreased when combined with Topiroxostat.Approved
TorasemidePhenylbutazone may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Phenylbutazone.Approved
TranilastThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Phenylbutazone.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Phenylbutazone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Triamcinolone.Approved, Vet Approved
TriamterenePhenylbutazone may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
TrimethoprimThe metabolism of Phenylbutazone can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Triptolide.Investigational
TrovafloxacinPhenylbutazone may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TroxerutinPhenylbutazone may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Phenylbutazone.Approved
Valproic AcidThe metabolism of Phenylbutazone can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinPhenylbutazone may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Phenylbutazone can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Phenylbutazone.Approved
VoriconazoleThe metabolism of Phenylbutazone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinPhenylbutazone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPhenylbutazone may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Phenylbutazone can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Phenylbutazone.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Phenylbutazone.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinPhenylbutazone may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinPhenylbutazone may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Take with food to reduce irritation. Avoid alcohol.

References

Synthesis Reference

Dieter Rahtz, Henning Koch, Erich Gerhards, "Hydroxy phenylbutazone derivatives and their preparation." U.S. Patent US3968219, issued January, 1971.

US3968219
General References
Not Available
External Links
Human Metabolome Database
HMDB14950
KEGG Drug
D00510
KEGG Compound
C07440
PubChem Compound
4781
PubChem Substance
46507038
ChemSpider
4617
ChEBI
48574
ChEMBL
CHEMBL101
Therapeutic Targets Database
DAP000974
PharmGKB
PA450932
HET
P1Z
Wikipedia
Phenylbutazone
ATC Codes
M01BA01 — Phenylbutazone and corticosteroidsM01AA01 — PhenylbutazoneM02AA01 — Phenylbutazone
PDB Entries
2bxc / 2bxp / 2bxq / 2w98
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Novartis pharmaceuticals corp
  • Ivax pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral100 mg
Prices
Unit descriptionCostUnit
Phenylbutazone powder1.16USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)105 °CPhysProp
water solubility47.5 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.16SANGSTER (1994)
logS-3.81ADME Research, USCD
pKa4.5SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility0.144 mg/mLALOGPS
logP2.81ALOGPS
logP4.14ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)5.13ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.62 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity88.76 m3·mol-1ChemAxon
Polarizability34.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9931
Caco-2 permeable+0.6185
P-glycoprotein substrateNon-substrate0.7632
P-glycoprotein inhibitor INon-inhibitor0.5423
P-glycoprotein inhibitor IIInhibitor0.5596
Renal organic cation transporterNon-inhibitor0.866
CYP450 2C9 substrateNon-substrate0.6378
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5439
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.5752
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.5968
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5233
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7995
BiodegradationNot ready biodegradable0.9881
Rat acute toxicity2.7753 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9469
hERG inhibition (predictor II)Non-inhibitor0.892
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.03 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0009000000-f8e4cda83d45cc4ca59b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0549000000-2907029e48d9c65ae00e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-2910000000-bb1ac78907a0338c7dc6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000x-6900000000-4f14a2268cc3ae06d3e5
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9400000000-d5012ae523568dc8e63c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9100000000-2af914d40adc6817f026
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-1b11164dde00c44d0ffe
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-9000000000-3b304315d58e9e8f6984
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00kf-9000000000-b6387c41c12a5abb6d4b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0009000000-bde0ac035aafd4e337f2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0092000000-e77e2c9ca9127d3ecff9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4l-0196000000-6d31987fe09f0949a98d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-016r-0190000000-6b839462a4e745d1fc0d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00vi-0290000000-c78339fd5994808afb08
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0109000000-c3cb4b19bc15bf87c709
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03kl-2921000000-02a08606b3d2e3c8c702
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01vo-5910000000-1e1a7cd346204d8387aa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9700000000-b87550cf5df8c862c64a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kf-9500000000-222c301c8bf7fa8c9490
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05mp-9400000000-435ce3b2edce024cf240
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0694-9300000000-6da14f0b017841074aae
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0v01-9200000000-7f2a34538722ab3db398
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-9100000000-9da3ad0823a2792e46cb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-2947000000-a91a724d8272a5a71f97

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Pyrazolidinones / 1,3-dicarbonyl compounds / Carboxylic acid hydrazides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Monocyclic benzene moiety / Pyrazolidinone / 1,3-dicarbonyl compound / Pyrazolidine / Carboxylic acid hydrazide / Azacycle / Organoheterocyclic compound / Carboxylic acid derivative / Organic oxide / Organopnictogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrazolidines (CHEBI:48574)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Arifah AK, Lees P: Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. J Vet Pharmacol Ther. 2002 Aug;25(4):299-309. [PubMed:12213119]
  2. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB: Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004 Dec 9;23(57):9247-58. [PubMed:15489888]
  3. Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6. [PubMed:15939622]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-i synthase activity
Specific Function
Catalyzes the isomerization of prostaglandin H2 to prostacyclin (= prostaglandin I2).
Gene Name
PTGIS
Uniprot ID
Q16647
Uniprot Name
Prostacyclin synthase
Molecular Weight
57103.385 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Reed GA, Griffin IO, Eling TE: Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone. Requirement for peroxidative metabolism. Mol Pharmacol. 1985 Jan;27(1):109-14. [PubMed:3917545]
  4. Marnett LJ, Siedlik PH, Ochs RC, Pagels WR, Das M, Honn KV, Warnock RH, Tainer BE, Eling TE: Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Mol Pharmacol. 1984 Sep;26(2):328-35. [PubMed:6434940]
  5. Tobin T, Chay S, Kamerling S, Woods WE, Weckman TJ, Blake JW, Lees P: Phenylbutazone in the horse: a review. J Vet Pharmacol Ther. 1986 Mar;9(1):1-25. [PubMed:3517382]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zitova A, Hynes J, Kollar J, Borisov SM, Klimant I, Papkovsky DB: Analysis of activity and inhibition of oxygen-dependent enzymes by optical respirometry on the LightCycler system. Anal Biochem. 2010 Feb 15;397(2):144-51. doi: 10.1016/j.ab.2009.10.029. Epub 2009 Oct 20. [PubMed:19849999]
  2. Beretta C, Garavaglia G, Cavalli M: COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6. [PubMed:15939622]
  3. Morton AJ, Campbell NB, Gayle JM, Redding WR, Blikslager AT: Preferential and non-selective cyclooxygenase inhibitors reduce inflammation during lipopolysaccharide-induced synovitis. Res Vet Sci. 2005 Apr;78(2):189-92. [PubMed:15563928]

Enzymes

Details
1. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  2. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697]
  3. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:45